Benefits
VO2 max improvement and oxygen utilization
PeakO2® supplementation (4 g/day for 21 days) produced a significant improvement in VO2 max of about 4 ml/kg/min, roughly an 8-9% increase in aerobic capacity. VO2 max is the single strongest predictor of cardiovascular fitness and endurance performance, making this a notable outcome for a non-pharmaceutical supplement.
Peak power output +17.6% in 7 days
Competitive athletes supplementing with 4 g/day PeakO2® for 7 days improved peak power output by 17.6% vs baseline, while the placebo group decreased 11.8%. This rapid power enhancement (within one week) compares favorably to creatine (3-4 weeks to peak) and beta-alanine (4-8 weeks), earning PeakO2® its '6 weeks faster' characterization.
Time to exhaustion and endurance extension
PeakO2® extended time to exhaustion by about 65 seconds over 21 days of supplementation — a meaningful improvement for athletes in events where pacing and endurance are critical. The blood lactate clearance improvement observed alongside VO2 max gains suggests multiple complementary mechanisms for endurance enhancement.
Immune support and adaptogenic stress resilience
The six mushrooms in PeakO2® — particularly Turkey Tail (beta-glucans, PSK, PSP), Reishi (triterpenes), and Lion's Mane (hericenones) — provide comprehensive immune modulation, NK cell activation, and adaptogenic stress resistance. These benefits extend PeakO2® beyond pure athletic performance into overall wellness, recovery, and immune resilience applications.
Mechanism of action
Oxygen uptake optimization and ATP efficiency
Cordyceps militaris bioactives (cordycepin, adenosine, beta-glucans) improve mitochondrial oxygen utilization efficiency — increasing the ATP yield per unit oxygen consumed. Combined with ergothioneine (a mitochondrial antioxidant that protects against exercise-induced oxidative damage) and beta-glucans (which support cardiovascular function), PeakO2® simultaneously improves the oxygen delivery system (VO2 max) and cellular energy conversion efficiency (ATP per O2).
Clinical trials
Two-arm clinical study at University of North Carolina Chapel Hill. Low-dose arm: 1-4 g/day × 28 days (40 subjects aged 18-50). Outcomes: VO2 max, time to exhaustion, blood lactate. (Hirsch et al. 2021, J Diet Suppl)
40 adults (low-dose arm).
Low-dose PeakO2® (28 days): VO2 max increased ~+4 ml/kg/min, time to exhaustion +65 sec, reduced blood lactate vs placebo. Industry-funded (Compound Solutions). Note: 40 subjects in low-dose arm; cardiorespiratory effects of magnitude reported are substantial — warrants independent replication.